Inflammatory marker interleukin-6 in risk stratification of COVID-19 patients
The main purpose of this study is to determine the levels of interleukin-6 in COVID-19 patients and see if these inflammatory markers can speculate the extremity of COVID-19 patients. Therefore, previous work on serum ferritin levels in COVID-19 patients has been conducted by the authors as a presumptive observational study . The study’s inclusion criteria comprised 100 individuals who were over the age of 18 and were diagnosed with COVID-19 by real-time quantitative reverse transcriptase polymerase chain reaction method for severe acute respiratory syndrome (SARS-CoV-2). The exclusion criterion was framed according to our previous study . They were bifurcated into the following categories such as: mild to moderate (Group I) and severe to critical (Group II). IL-6 was quantified and evaluated in both groups using the chemiluminescent method . Group I had a mean IL 6 value of 27 pg/ml, while Group II had a value of 126 pg/ml. COVID-19 individuals with elevated IL-6 levels had more indicative predictions, extremity, and serious illness, particularly in group II (P<0.000), and constant in group I, IL-6 levels showed a statistically significant (P<0.000) association with symptomatic indications, severity, and critical illness. Interleukin-6 can be used as a prediction factor for disease severity in the early diagnosis of COVID-19.